Year Founded
2009
Ownership
Private
Employees
~10
Therapeutic Areas
RheumatologyOncologyImmunologyPulmonology
Stage
Phase 1
Modalities
Antibody-based immunotherapyAntibody-drug conjugate (ADC)

Inatherys General Information

Lead candidate INA03 (anti-CD71 ADC) in Phase 1 clinical trials (NCT03957915) for acute leukemia. INA02 (anti-CD89) in preclinical development for inflammatory diseases.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

INA03
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Inatherys's pipeline data

Book a demo

Key Partnerships

Syndivia

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Inatherys Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Inatherys's complete valuation and funding history, request access »